Cited by 150Endometriosis Research and TreatmentEctopic Pregnancy Diagnosis and ManagementGynecological conditions and treatments

Biomarkers of endometriosis

Open access
Fassbender, Amelie, Vodolazkaia, Alexandra, Saunders, Philippa, Lebovic, Dan, Waelkens, Etienne, De Moor, Bart, D'Hooghe, Thomas·2013·Fertility and Sterility

Abstract

A noninvasive test for endometriosis would be useful for the early detection of endometriosis in symptomatic women who have pelvic pain and/or subfertility with normal ultrasound results. This would include nearly all cases of minimal-to-mild endometriosis, some cases of moderate-to-severe endometriosis without a clearly visible ovarian endometrioma, and cases with pelvic adhesions and/or other pelvic pathology that might benefit from surgery to improve pelvic pain and/or subfertility. This overview discusses the diagnostic performance of noninvasive or semi-invasive tests for endometriosis, including panels of known peripheral blood biomarkers, protein/peptide markers discovered by proteomics, miRNA, and endometrial nerve fiber density. Tests with high sensitivity and acceptable specificity have been developed; some have been validated in independent populations and are therefore promising. To make real progress, international agreement on biobank development is needed for standard operating procedures for the collection, treatment, storage, and analysis of tissue samples and for detailed clinical phenotyping of these samples. Furthermore, it is necessary to validate the diagnostic accuracy of any promising test prospectively in an independent symptomatic patient population with subfertility and/or pain without clear ultrasound evidence of endometriosis and with a clinical indication for surgery, divided into cases with laparoscopically and histologically confirmed endometriosis and controls with laparoscopically confirmed absence of endometriosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.fertnstert.2013.01.097

Cites

152 of 152 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • At present, no noninvasive test with high sensitivity for endometriosis exists.

    “At present, such a test does not exist [17, 20].”

    From Update on biomarkers for the detection of endometriosis (2015) · cites this paper as [17]

  • Putative endometriosis biomarkers are mostly glycoproteins, growth or adhesion factors, hormones, or proteins related to immunology or angiogenesis.

    “Putative endometriosis biomarkers are mostly glycoproteins, growth or adhesion factors, hormones, or proteins related to immunology or angiogenesis [17, 23, 30].”

    From Update on biomarkers for the detection of endometriosis (2015) · cites this paper as [17]

  • Despite extensive research, no single biomarker nor a panel of biomarkers in peripheral blood has been validated as a diagnostic test for endometriosis.

    “Despite extensive research, no single biomarker nor a panel of biomarkers in peripheral blood has been validated as a diagnostic test for endometriosis [17, 20].”

    From Update on biomarkers for the detection of endometriosis (2015) · cites this paper as [17]

  • Proteomics technologies are costly and time-consuming, and there is a need for better standardization and reproducibility before they can be used reliably in clinical research projects.

    “These studies have shown promising results; however, proteomics technologies are costly and time-consuming [23], and there is a need for better standardization and reproducibility of proteomic technologies before they can be used reliably in clinical research projects [17].”

    From Update on biomarkers for the detection of endometriosis (2015) · cites this paper as [17]

  • This can allow researchers to overcome the main pitfalls in the study design and methodology such as small sample size, lack of relevant clinical information inconsistency in sample handling and storage, and technical control of preanalytical sample variability, which contribute to controversial study results in endometriosis research.

    “This can allow researchers to overcome the main pitfalls in the study design and methodology such as small sample size, lack of relevant clinical information inconsistency in sample handling and storage, and technical control of preanalytical sample variability, which contribute to controversial study results in endometriosis research [17].”

    From Update on biomarkers for the detection of endometriosis (2015) · cites this paper as [17]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

2 retracted

Flagged first, then by citations

2 of the 154 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Becker JCDR, Hartmann AA, Burg G, Schmidt RE. Schedding of ICAM-1 from human melanoma cell lines induced by INF-g and tumor necrosis factor-alpha: functional consequence of cell-mediated cytotoxicity. J Immunol 1991;11:3788-93.

Cited by

Sorted by citations

Authors
Fassbender, A., Vodolazkaia, A., Saunders, P., Lebovic, D., Waelkens, E., De Moor, B., & D'Hooghe, T.
Affiliations
  • Universitair Ziekenhuis Leuven (BE)
  • MRC Centre for Reproductive Health (GB)
  • University of Wisconsin–Madison (US)
  • KU Leuven (BE)
Venue
Fertility and Sterility
Publisher
Elsevier BV
Published
2013-03
Volume
99
Issue
4
Pages
1135-1145
ISSN
0015-0282 (ISSN-L)
OpenAlex
W2151444028
Cited by
150
References
154
Citations by year
2026: 2 · 2025: 5 · 2024: 3 · 2023: 8 · 2022: 10 · 2021: 5 · 2020: 12 · 2019: 14 · 2018: 16 · 2017: 13 · 2016: 17 · 2015: 17 · 2014: 21 · 2013: 7
FWCI
3.35
Type
journal article
Language
en
Open access
Locations
  • Fertility and Sterility (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ectopic Pregnancy Diagnosis and Management
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
Keywords
endometriosis, biomarkers, non-invasive diagnosis, peripheral blood biomarkers, proteomics, microRNA, subfertility, pelvic pain, diagnostic accuracy, endometrioma
MeSH terms
Endometriosis, Endometrium, Female, Humans, Reproducibility of Results, Biomarkers, Proteomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review